Canada markets open in 3 hours 5 minutes

Cellectis S.A. (CLLS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.6700+0.1700 (+6.80%)
At close: 04:00PM EDT
2.7500 +0.08 (+3.00%)
Pre-Market: 05:44AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.5000
Open2.5600
Bid2.4000 x 1100
Ask2.5500 x 100
Day's Range2.5022 - 2.7050
52 Week Range0.9630 - 3.7740
Volume7,359
Avg. Volume44,057
Market Cap191.576M
Beta (5Y Monthly)3.13
PE Ratio (TTM)N/A
EPS (TTM)-1.4100
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.43
  • GlobeNewswire

    Monthly information on share capital and company voting rights

    PARIS, March 04, 2024 (GLOBE NEWSWIRE) -- (Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights02/29/202471,751,20177,686,895 For further information on Cellectis, please contact: Media contact: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 4

  • GlobeNewswire

    Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)

    NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it has drawn down the second tranche of €15 million (“Tranche B”) under the credit facility agreement for up to €40 million entered into with the European Investment Bank (the “EIB) on December 28, 2022 (the "Finance Contract"). Tranche B

  • GlobeNewswire

    Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

    NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. At the meeting, resolutions 1 through 5 as well as resolutions 7 and 8 were adopted and resolution 6 was rejected, consistent with the recommenda